Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $208 | $69 | $79 | $224 |
| Short-Term Investments | $183 | $221 | $248 | $148 |
| Receivables | $5 | $2 | $1 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $6 | $7 | $5 | $5 |
| Total Curr. Assets | $402 | $299 | $332 | $377 |
| Property Plant & Equip (Net) | $53 | $55 | $56 | $56 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $5 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $5 | $0 | $5 | $5 |
| Total NC Assets | $58 | $60 | $61 | $61 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $460 | $360 | $393 | $439 |
| Liabilities | – | – | – | – |
| Payables | $15 | $6 | $6 | $17 |
| Short-Term Debt | $4 | $4 | $4 | $4 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $25 | $18 | $33 | $117 |
| Other Curr. Liab. | $18 | $14 | $16 | $19 |
| Total Curr. Liab. | $61 | $42 | $59 | $157 |
| LT Debt | $36 | $37 | $38 | $39 |
| Deferred Rev, NC | $0 | $8 | $17 | $16 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $117 | $5 | $4 | $4 |
| Total NC Liab. | $153 | $50 | $59 | $59 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $41 | $42 | $43 |
| Total Liabilities | $214 | $92 | $118 | $216 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$431 | -$404 | -$392 | -$439 |
| AOCI | -$3 | -$3 | -$3 | -$3 |
| Other Equity | $680 | $675 | $670 | $665 |
| Total Equity | $246 | $268 | $275 | $223 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $460 | $360 | $393 | $439 |
| Net Debt | -$168 | -$28 | -$37 | -$182 |